» Articles » PMID: 33808215

Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors

Abstract

Cutaneous squamous cell carcinomas (cSCCs) account for about 20% of keratinocyte carcinomas, the most common cancer in the UK. Therapeutic options for cSCC patients who develop metastasis are limited and a better understanding of the biochemical pathways involved in cSCC development/progression is crucial to identify novel therapeutic targets. Evidence indicates that the phosphoinositide 3-kinases (PI3Ks)/Akt pathway plays an important role, in particular in advanced cSCC. Questions remain of whether all four PI3K isoforms able to activate Akt are involved and whether selective inhibition of specific isoform(s) might represent a more targeted strategy. Here we determined the sensitivity of four patient-derived cSCC cell lines to isoform-specific PI3K inhibitors to start investigating their potential therapeutic value in cSCC. Parallel experiments were performed in immortalized keratinocyte cell lines. We observed that pan PI3Ks inhibition reduced the growth/viability of all tested cell lines, confirming the crucial role of this pathway. Selective inhibition of the PI3K isoform p110α reduced growth/viability of keratinocytes and of two cSCC cell lines while affecting the other two only slightly. Importantly, p110α inhibition reduced Akt phosphorylation in all cSCC cell lines. These data indicate that growth and viability of the investigated cSCC cells display differential sensitivity to isoform-specific PI3K inhibitors.

Citing Articles

Arctigenin inhibits the progression of colorectal cancer through epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway.

Chen X, Liu P, Sheng N, Li X, Hu R, Zhu L PLoS One. 2024; 19(9):e0308947.

PMID: 39331595 PMC: 11432899. DOI: 10.1371/journal.pone.0308947.


Transglutaminase 3 regulates cutaneous squamous carcinoma differentiation and inhibits progression via PI3K-AKT signaling pathway-mediated Keratin 14 degradation.

Zhou K, Wu C, Cheng W, Zhang B, Wei R, Cheng D Cell Death Dis. 2024; 15(4):252.

PMID: 38589352 PMC: 11001918. DOI: 10.1038/s41419-024-06626-5.


PIK Your Poison: The Effects of Combining PI3K and CDK Inhibitors against Metastatic Cutaneous Squamous Cell Carcinoma In Vitro.

Perry J, Genenger B, Thind A, Ashford B, Ranson M Cancers (Basel). 2024; 16(2).

PMID: 38254859 PMC: 10814950. DOI: 10.3390/cancers16020370.


Case report: PIK3CA somatic mutation leading to Klippel Trenaunay Syndrome and multiple tumors.

Serio V, Palmieri M, Innamorato S, Loberti L, Fallerini C, Ariani F Front Genet. 2023; 14:1213283.

PMID: 37662840 PMC: 10469863. DOI: 10.3389/fgene.2023.1213283.


KIFC3 Promotes Proliferation, Migration, and Invasion in Colorectal Cancer PI3K/AKT/mTOR Signaling Pathway.

Liao H, Zhang L, Lu S, Li W, Dong W Front Genet. 2022; 13:848926.

PMID: 35812733 PMC: 9257096. DOI: 10.3389/fgene.2022.848926.


References
1.
Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I . Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012; 367(4):329-39. DOI: 10.1056/NEJMoa1204166. View

2.
Burton K, Ashack K, Khachemoune A . Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease. Am J Clin Dermatol. 2016; 17(5):491-508. DOI: 10.1007/s40257-016-0207-3. View

3.
Sayama K, Yamasaki K, Hanakawa Y, Shirakata Y, Tokumaru S, Ijuin T . Phosphatidylinositol 3-kinase is a key regulator of early phase differentiation in keratinocytes. J Biol Chem. 2002; 277(43):40390-6. DOI: 10.1074/jbc.M112423200. View

4.
Pomel V, Klicic J, Covini D, Church D, Shaw J, Roulin K . Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J Med Chem. 2006; 49(13):3857-71. DOI: 10.1021/jm0601598. View

5.
Green J, Ikram M, Vyas J, Patel N, Proby C, Ghali L . Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours. Br J Cancer. 2006; 94(10):1446-51. PMC: 2361292. DOI: 10.1038/sj.bjc.6603135. View